Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

IRE1

Inositol-requiring enzyme 1 (IRE1) is a bifunctional serine/threonine kinase and endoribonuclease that is a major mediator of the unfolded protein response (UPR) during endoplasmic reticulum (ER) stress. It represents a potential therapeutic target for a number of diseases associated with endoplasmic reticulum stress. IRE1 is the only identified ER stress sensor in yeast and essential for UPR in animals and plants. As an ER transmembrane protein, IRE1 monitors ER homeostasis through an ER luminal stress-sensing domain and triggers UPR through a cytoplasmic kinase domain and an RNase domain. Upon ER stress, IRE1 RNase is activated through conformational change, autophosphorylation, and higher order oligomerization. Mammalian IRE1 initiates diverse downstream signaling of the UPR either through unconventional splicing of the transcription factor Xbp-1 or and through posttranscriptional modifications via Regulated IRE1-Dependent Decay (RIDD) of multiple substrates.

D-F07
T843112361297-58-5In house
D-F07 is a novel fluorescent IRE-1 RNase inhibitor and a tricyclic chromone with potential anticancer activity.
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Hot
4μ8C
T636314003-96-4
4μ8C (IRE1 Inhibitor III)(IC50=76 nM) is an effective and specific IRE1 Rnase inhibitor.
  • $43
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
APY29
T36541216665-49-4
APY29 is an allosteric modulator of IRE1α; inhibits IRE1α autophosphorylation (IC50 = 280 nM) and activates IRE1α RNase activity.
  • $36
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Kira8
T11762L1630086-20-2
Kira8 (AMG-18) is a mono-selective IRE1α inhibitor that allosterically attenuates IRE1α RNase activity with an IC50 of 5.9 nM.
  • $89
In Stock
Size
QTY
Sunitinib
T0374L557795-19-4
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that inhibits VEGFR2 and PDGFRβ (IC50=80 2 nM). It exhibits antitumor activity and is used for treating kidney cancer and gastrointestinal tumors.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
MKC8866
T155941338934-59-0
MKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29 μM in human vitro). MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibit prostate cancer (PCa) tumor growth.
  • $80
In Stock
Size
QTY
STF-083010
T6681307543-71-1
STF-083010 is a selective inhibitor of the IRE1α endonuclease.
  • $47
In Stock
Size
QTY
TargetMol | Citations Cited
IXA4
T93491185329-96-7
IXA4 is a highly selective, nontoxic activator of IRE1/XBP1s and reduces APP secretion by activating IRE1. IXA4-stimulated IRE1 activation also enhanced pancreatic function.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
IRE1α kinase-IN-1
T95642328097-41-0
IRE1α kinase-IN-1 is a highly selective IRE1α (ERN1) inhibitor, with an IC50 of 77 nM, displaying 100-fold selectivity over the IRE1β isoform. It inhibits ER stress-induced IRE1α oligomerization and autophosphorylation, as well as IRE1α RNase activity (IC50=80 nM).
  • $118
In Stock
Size
QTY
GSK2850163 (S enantiomer)
T98482309519-81-9In house
GSK2850163 (S enantiomer) is the inactive enantiomer of GSK2850163. GSK2850163 is an novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1a).
  • $70
Backorder
Size
QTY
B I09
T148471607803-67-7In house
B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.
  • $44
In Stock
Size
QTY
Toyocamycin
T17143606-58-6
Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycetes, functioning as an XBP1 inhibitor and inhibiting IRE1α-induced ATP-dependent XBP1 mRNA cleavage (IC50: 80 nM), and induces apoptosis.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
KIRA6
TQ00761589527-65-0
KIRA6 is an effective inhibitor of IRE1α RNase kinase (IC50: 0.6 μM). It can trigger an apoptotic response.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
Sunitinib Malate
T0374341031-54-7
Sunitinib Malate (Sunitinib) is an indolinone-based tyrosine kinase inhibitor. It blocks the tyrosine kinase activities of VEGFR2, PDGFRβ (IC50: 80/2 nM), and c-kit.
  • $30
In Stock
Size
QTY
MKC9989
T120711338934-20-5
MKC9989 is an inhibitor of Hydroxy aryl aldehydes (HAA). MKC9989 also inhibits IRE1α with an IC50 of 0.23 to 44 μM.
  • $47
In Stock
Size
QTY
GSK2850163
T114882121989-91-9In house
GSK2850163 is a novel inhibitor of inositol-requiring enzyme-1 alpha (IRE1α), effectively inhibiting both its RNase activity and IRE1α kinase activity (IC50s: 200 and 20 nM).
  • $64
In Stock
Size
QTY
IXA6
T625681021106-40-0
IXA6, a novel IRE1 XBP1s agonist with potential vasoprotective activity, activates IRE1-XBP1s signaling and XBP1s transcriptional response, making it useful for studying neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.
  • $299
In Stock
Size
QTY
MKC3946
TQ01011093119-54-0
MKC3946 is an effective and soluble IRE1α inhibitor which triggered modest growth inhibition in multiple myeloma cell lines.
  • $61
In Stock
Size
QTY
TargetMol | Inhibitor Sale
6-Bromo-2-hydroxy-3-methoxybenzaldehyde
T748320035-41-0
6-Bromo-2-hydroxy-3-methoxybenzaldehyde (NSC-95682) is an inhibitor of IRE-1α with an IC50 value of 0.08 μM.
  • $35
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Z4P
T876582361760-87-2
Z4P, an IRE1 inhibitor with blood-brain barrier permeability (BBB) (IC50=1.13 μM), inhibits glioblastoma growth and recurrence in combination with Temozolomide.
  • $74
In Stock
Size
QTY
3,6-DMAD dihydrochloride
T625062226511-77-7In house
3,6-DMAD dihydrochloride is an acridine derivative and a potent inhibitor of the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride can induce IL-6 secretion by exploiting the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride is a potent inhibitor of the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride has inhibitory effects on IRE1α oligomerization and RNase activity. 3,6-DMAD dihydrochloride can be used in cancer research.
  • $1,520
6-8 weeks
Size
QTY
IRE1-IN-2
T207625
IRE1-IN-2 (compound G15) functions as a potent inhibitor of IRE1. It effectively suppresses lipid accumulation induced by FFA, exhibiting an IC50 value of 2.06 μM.
  • Inquiry Price
Size
QTY
GP29
T240991415050-59-7
GP29 is a Type II kinase inhibitor of the IRE1α endoribonuclease that acts by targeting the ATP-binding pocket of IRE1α.
  • $1,520
6-8 weeks
Size
QTY
GSK2850163 hydrochloride
T631982319838-09-8
GSK2850163 hydrochloride is a novel inositol-requiring enzyme-1α (IRE1α) inhibitor that inhibits the kinase (IC50: 20 nM) and RNA enzyme (IC50: 200 nM) activities of IRE1α.
  • $1,520
1-2 weeks
Size
QTY